UBS reduced Chemours’ price target and downgraded the stock after a sharper refrigerants reset hurt medium-term growth visibility.
UBS downgraded Chemours to Neutral from Buy and lowered its price target, citing a sharper-than-anticipated decline in the company’s refrigerants business. The move reflects reduced confidence in Chemours’ medium-term growth outlook due to excess channel inventory and weaker earnings expectations.
The bank cut earnings estimates by 7%-12% for 2026-2028, with the steepest reductions in the refrigerants segment. UBS expects growth to rebound later, driven by recovery in TiO2 and advanced materials, though risks remain from weak pricing and higher PFAS liabilities.
Chemours shares fell following the downgrade, as the outlook shift balances risk-reward prospects with limited near-term visibility.